A double-blind, double-dummy, randomized, placebo- and active-controlled, three-way crossover study to evaluate the effect of Budesonide/Formoterol Spiromax 80/4.5 mcg Inhalation Powder and Symbicort Turbohaler 100/6 mcg on the short-term lower leg growth rate in prepubescent children with persistent asthma.

Trial Profile

A double-blind, double-dummy, randomized, placebo- and active-controlled, three-way crossover study to evaluate the effect of Budesonide/Formoterol Spiromax 80/4.5 mcg Inhalation Powder and Symbicort Turbohaler 100/6 mcg on the short-term lower leg growth rate in prepubescent children with persistent asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2012

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 22 Mar 2012 Additional trial location added as reported by European Clinical Trials Database,
    • 22 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top